Developer docs
API playgroundTry for free, no card

Search company profiles

Lexaria Bioscience

Full company profile

uuid0000zl5

Namestring
Lexaria Bioscience
Legal namestring
Lexaria Bioscience Corp.
Company typeenum
Public
Founded yearint
2014
Descriptiontext

Lexaria Bioscience Corp. (NASDAQ:LEXX) is a clinical-stage biotechnology company that develops and out-licenses its proprietary DehydraTECH drug delivery platform. DehydraTECH is a patented process that mixes active pharmaceutical ingredients (APIs) with fatty acid-rich triglyceride oils and infuses the mixture into substrate materials via controlled dehydration synthesis, enabling molecular association of payload and oils. The technology is applicable to small and large molecule therapeutics (including GLP-1 peptides), works across tablets, capsules, oral suspensions, and consumable liquids, supports both hepatic and lymphatic transport pathways, masks taste and odor, and has demonstrated blood-brain barrier penetration. The platform is protected by 65 granted patents across the US, Australia, EU, Japan, Mexico, Canada, and India, with additional applications pending.

The company monetizes DehydraTECH through three revenue streams: (1) technology licensing to pharmaceutical, nutraceutical, and consumer product companies via up-front fees, milestone payments, and royalties; (2) toll processing of GMP-grade intermediate formulations for corporate clients; and (3) contract research and formulation services, including CRO contracts and Material Transfer Agreements with pharmaceutical partners evaluating DehydraTECH with specific APIs. Named enterprise relationships include Altria (smokeless nicotine), Novo Nordisk (semaglutide/amycretin evaluation), an unnamed PharmaCO under an MTA extended through December 2026 with a temporary exclusive license in GLP-1, plus consumer-facing licensees Nic's Beverages and Amari Corp.

Lexaria is incorporated in Nevada, headquartered in Kelowna, BC (Canada), with US operations in Tyrone, GA, and operates through five wholly-owned subsidiaries (Lexaria Pharmaceutical Corp., Lexaria Nicotine LLC, Lexaria Hemp Corp., Lexaria Canpharm ULC, Lexaria Nutraceutical Corp.) plus patent-holding Poviva Corp. Recent clinical milestones include the December 2025 Phase 1b GLP-1-H24-4 primary endpoint readout showing 48% lower overall side effects versus Rybelsus, alongside granted patents covering diabetes, hypertension, antivirals, epilepsy, and sublingual nicotine delivery.

Short descriptiontext

Lexaria Bioscience Corp. (NASDAQ:LEXX) is a clinical-stage biotechnology company that develops and out-licenses its proprietary DehydraTECH drug delivery platform, which improves oral bioavailability of active pharmaceutical ingredients for pharmaceutical, nutraceutical, and consumer product partners worldwide.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersKelowna, Canada
HQ citystring
Kelowna
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug delivery platform, oral bioavailability technology, pharmaceutical technology licensing, GLP-1 formulation, CBD absorption technology
Industry2 codes
PRIMARYAFAJACAF
Hydrocolloid Stabilizers (Xanthan, Guar, Locust Bean, Carrageenan, Alginate, Pectin, Cellulose)
Agriculture & Food Production/Food Ingredients & Additives/Emulsifiers & Stabilizers (Lecithin, Mono/Diglycerides, Stabilizer Systems)
SECONDARYAFAJACAK
Beverage Emulsions & Clouding Agents (Flavor Emulsions, Weighting Agents)
Agriculture & Food Production/Food Ingredients & Additives/Emulsifiers & Stabilizers (Lecithin, Mono/Diglycerides, Stabilizer Systems)
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Medicinal and Botanical Manufacturing325411
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Drug Delivery Technology
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Technology Licensing
TypeLicensing Royalties
Description

Lexaria out-licenses its DehydraTECH technology to pharmaceutical, nutraceutical, and consumer product companies in exchange for up-front fees, milestone payments, and/or royalty payments. Licensing covers the delivery of fat-soluble active molecules and drugs.

lexariabioscience.com
2Toll Processing
TypeProfessional Services
Description

Lexaria offers dietary supplement GMP-grade intermediate formulations to corporate clients on a toll processing basis, providing manufacturing/processing services for DehydraTECH-enhanced products.

lexariabioscience.com
3Research and Development Services
TypeProfessional Services
Description

Lexaria conducts contract research and formulation development services for pharmaceutical partners, including CRO contracts for GLP-1 studies and material transfer agreements (MTAs) with pharmaceutical companies evaluating DehydraTECH.

lexariabioscience.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1DehydraTECH
Description

Proprietary drug delivery-enabling technology that improves the absorption of active pharmaceutical ingredients into the bloodstream, allowing greater drug effectiveness often with reduced side effects.

lexariabioscience.com
+3 more records
Core offering1 text field

Lexaria Bioscience develops and out-licenses its proprietary DehydraTECH drug delivery platform technology, which enhances oral absorption of fat-soluble active pharmaceutical ingredients (APIs) and bioactive compounds. The technology uses fatty acid-rich triglyceride oils and controlled dehydration synthesis to associate payloads at a molecular level, enabling improved bioavailability, taste/odor masking, blood-brain barrier crossing, and reduced gastrointestinal side effects. Lexaria monetizes DehydraTECH through licensing deals, contract research, and toll processing services to pharmaceutical, biotech, and consumer product companies worldwide.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • DehydraTECH-semaglutide reduced overall side effects by 48% compared to Rybelsus; gastrointestinal side effects reduced by 55%
+7 more records
Product overview1 text field

Lexaria Bioscience Corp. is a biotechnology company offering its proprietary DehydraTECH drug delivery platform technology, which improves oral absorption of APIs. The core offering is DehydraTECH, available in versions including DehydraTECH 2.0 for enhanced performance. The company operates five subsidiaries: Lexaria Pharmaceutical Corp. (pharmaceuticals for hypertension, antivirals, epilepsy), Lexaria Nicotine LLC (oral nicotine products), Lexaria Hemp Corp. (hemp B2B), Lexaria Canpharm ULC (Health Canada licensed lab), and Lexaria Nutraceutical Corp. (consumer goods). Key product applications include DehydraTECH-CBD for hypertension, DehydraTECH-GLP-1 for diabetes/weight loss, and DehydraTECH-Nicotine for oral delivery. The company licenses its technology to pharmaceutical and consumer product companies worldwide.

Product and service7 records
1DehydraTECH
CategoryDrug Delivery Platform
Description

Patented drug delivery platform technology that improves oral absorption of APIs into the bloodstream by mixing payloads with fatty acid-rich triglyceride oils and using controlled dehydration synthesis. Applicable to small and large molecule therapeutics in tablets, capsules, oral suspensions, and consumable liquids. Licensed to pharmaceutical, nutraceutical, and consumer product companies.

2DehydraTECH 2.0
CategoryDrug Delivery Platform
Description

Enhanced second-generation formulation of DehydraTECH demonstrating up to 2,708% more CBD delivery into bloodstream compared to MCT control formulations in animal studies.

3DehydraTECH-CBD
CategoryDrug Delivery Platform
Description

CBD formulations processed with DehydraTECH for potential treatment of hypertension, heart disease, and seizure disorders. Demonstrated up to 23% blood pressure reduction in human clinical studies.

4DehydraTECH-GLP-1
CategoryDrug Delivery Platform
Description

GLP-1 drug formulations (semaglutide, tirzepatide, liraglutide) enhanced with DehydraTECH to enable oral delivery and reduce gastrointestinal side effects compared to injectable formulations. DehydraTECH-semaglutide reduced overall side effects by 48% compared to Rybelsus.

5DehydraTECH-Nicotine
CategoryDrug Delivery Platform
Description

Oral nicotine formulations using DehydraTECH technology for faster blood absorption (10x to 20x faster than controls) and improved delivery compared to conventional oral nicotine products, including oral pouches and sublingual delivery.

6Toll Processing Services
CategoryContract Manufacturing
Description

GMP-grade intermediate formulations provided to corporate clients on a toll processing basis for DehydraTECH-enhanced dietary supplements and consumer products.

7Contract Research and Formulation Development Services
CategoryResearch Services
Description

Research partnerships and CRO contracts for pharmaceutical partners evaluating DehydraTECH, including Material Transfer Agreements (MTAs) and pre-clinical/clinical study services for GLP-1, antiviral, and other applications.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1PharmaCO (Unnamed Pharmaceutical Company)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-04
Description

Material Transfer Agreement (MTA) with an unnamed pharmaceutical company (referred to as 'PharmaCO') to evaluate DehydraTECH drug delivery technology for GLP-1 applications in a pre-clinical setting. The agreement was originally entered September 4, 2024 and extended through December 31, 2026. The extension maintains a temporary exclusive license and enables continued strategic planning discussions between the parties. Three GLP-1 studies are ongoing under this arrangement.

in.investing.com
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Licensing agreement with Altria for the development of smokeless, oral-based nicotine products using DehydraTECH technology. Lexaria provides DehydraTECH powder-based nicotine formulations to be evaluated by Altria under agreements effective until March 31, 2023.

Strategic tierMinorTypeOEM/ Whitelabel/ Licensing Partner
Description

Licensed DehydraTECH technology to Nic's Beverages (owners of Nic's Cold Brew brand) for use in CBD beverages. Lexaria prepared proprietary DehydraTECH-powered CBD nanoemulsions for the company, demonstrating 93.4% potency retention after one year.

Strategic tierMinorTypeOEM/ Whitelabel/ Licensing Partner
Description

Amari Corp. uses DehydraTECH technology in their 'Everyday Calm' CBD product, which was named a Top CBD Product Pick by New Hope Network (host of Natural Products Expo).

5Unnamed Multinational Pharmaceutical Companies (Multiple)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Lexaria is in early-stage discussions with several multinational pharmaceutical companies regarding its oral GLP-1 drug delivery technology. These discussions are aimed at exploring potential licensing or partnership agreements for DehydraTECH in the GLP-1 space.

investing.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers9 records
TypeDirect peer
Description

Oral drug delivery platform company developing thin-film and other proprietary oral formulation technologies for pharmaceutical partners. Directly comparable as a small-cap oral drug delivery licensor pursuing pharma partnerships and reformulation opportunities.

TypeDirect peer
Description

Pharmaceutical company built around a proprietary 3D-printing oral dosage form technology (ZipDose) for enhanced drug delivery. Comparable as a technology-licensing pharma focused on novel oral administration of established molecules.

TypeDirect peer
Description

Clinical-stage pharma developing an oral delivery platform (Protein Oral Delivery, POD) for peptides and proteins, including oral insulin and oral GLP-1. Directly comparable as a small-cap oral peptide delivery company pursuing pharma licensing.

4Emisphere Technologies
TypeDirect peer
Description

Pioneer in oral drug delivery using the Eligen carrier technology to enable absorption of macromolecules. Closely comparable to Lexaria as an oral bioavailability platform licensor to large pharma partners.

TypeDirect peer
Description

Specialty pharma built on proprietary drug delivery technologies (e.g., BEMA, BioErodible MucoAdhesive) for pain and addiction therapies. Comparable as a delivery-platform-driven pharma pursuing both in-house and partner products.

6Enteris BioPharma
TypeDirect peer
Description

Clinical-stage oral peptide delivery company offering Peptelligence and ProPerma formulation technologies and contract manufacturing. Comparable to Lexaria for its focus on oral peptide/GLP-1 reformulation and pharma partnership model.

TypeDirect peer
Description

Drug delivery company developing the CUREform platform for oral thin-film and multi-layer tablets with improved bioavailability. Comparable as a small-cap proprietary oral delivery technology licensor.

TypeBroad incumbent
Description

Large global drug delivery and contract development/manufacturing organization offering a wide range of bioavailability-enhancing formulation services across multiple modalities. Comparable as an incumbent oral bioavailability and drug delivery partner, though at much greater scale and breadth than Lexaria.

TypeBroad incumbent
Description

Global contract development and manufacturing organization serving pharma and biotech with drug substance, drug product, and specialized delivery capabilities including oral bioavailability. Comparable as a broad incumbent in pharma drug delivery services that Lexaria competes against for partner attention.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries6 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lexaria Bioscience

Drug Delivery Technologylexariabioscience.com

Lexaria Bioscience Corp. (NASDAQ:LEXX) is a clinical-stage biotechnology company that develops and out-licenses its proprietary DehydraTECH drug delivery platform, which improves oral bioavailability of active pharmaceutical ingredients for pharmaceutical, nutraceutical, and consumer product partners worldwide.

What Lexaria Bioscience does

Lexaria Bioscience Corp. (NASDAQ:LEXX) is a clinical-stage biotechnology company that develops and out-licenses its proprietary DehydraTECH drug delivery platform. DehydraTECH is a patented process that mixes active pharmaceutical ingredients (APIs) with fatty acid-rich triglyceride oils and infuses the mixture into substrate materials via controlled dehydration synthesis, enabling molecular association of payload and oils. The technology is applicable to small and large molecule therapeutics (including GLP-1 peptides), works across tablets, capsules, oral suspensions, and consumable liquids, supports both hepatic and lymphatic transport pathways, masks taste and odor, and has demonstrated blood-brain barrier penetration. The platform is protected by 65 granted patents across the US, Australia, EU, Japan, Mexico, Canada, and India, with additional applications pending.

The company monetizes DehydraTECH through three revenue streams: (1) technology licensing to pharmaceutical, nutraceutical, and consumer product companies via up-front fees, milestone payments, and royalties; (2) toll processing of GMP-grade intermediate formulations for corporate clients; and (3) contract research and formulation services, including CRO contracts and Material Transfer Agreements with pharmaceutical partners evaluating DehydraTECH with specific APIs. Named enterprise relationships include Altria (smokeless nicotine), Novo Nordisk (semaglutide/amycretin evaluation), an unnamed PharmaCO under an MTA extended through December 2026 with a temporary exclusive license in GLP-1, plus consumer-facing licensees Nic's Beverages and Amari Corp.

Lexaria is incorporated in Nevada, headquartered in Kelowna, BC (Canada), with US operations in Tyrone, GA, and operates through five wholly-owned subsidiaries (Lexaria Pharmaceutical Corp., Lexaria Nicotine LLC, Lexaria Hemp Corp., Lexaria Canpharm ULC, Lexaria Nutraceutical Corp.) plus patent-holding Poviva Corp. Recent clinical milestones include the December 2025 Phase 1b GLP-1-H24-4 primary endpoint readout showing 48% lower overall side effects versus Rybelsus, alongside granted patents covering diabetes, hypertension, antivirals, epilepsy, and sublingual nicotine delivery.

Lexaria Bioscience firmographics

Firmographics
Name
Lexaria Bioscience
Legal name
Lexaria Bioscience Corp.
Website
https://lexariabioscience.com
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
1–10 employees
Short description
Lexaria Bioscience Corp. (NASDAQ:LEXX) is a clinical-stage biotechnology company that develops and out-licenses its proprietary DehydraTECH drug delivery platform, which improves oral bioavailability of active pharmaceutical ingredients for pharmaceutical, nutraceutical, and consumer product partners worldwide.
Ownership category
akta.pro rank

Lexaria Bioscience industry classification

Industry
Product category
Drug Delivery Technology
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYAFAJACAF
Hydrocolloid Stabilizers (Xanthan, Guar, Locust Bean, Carrageenan, Alginate, Pectin, Cellulose)
Agriculture & Food Production/Food Ingredients & Additives/Emulsifiers & Stabilizers (Lecithin, Mono/Diglycerides, Stabilizer Systems)
SECONDARYAFAJACAK
Beverage Emulsions & Clouding Agents (Flavor Emulsions, Weighting Agents)
Agriculture & Food Production/Food Ingredients & Additives/Emulsifiers & Stabilizers (Lecithin, Mono/Diglycerides, Stabilizer Systems)

Keywords

  • Drug delivery platform
  • Oral bioavailability technology
  • Pharmaceutical technology licensing
  • GLP-1 formulation
  • CBD absorption technology

Where Lexaria Bioscience is headquartered

Location

Headquarters

HQ city
Kelowna
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

Lexaria Bioscience business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. Technology Licensing: Lexaria out-licenses its DehydraTECH technology to pharmaceutical, nutraceutical, and consumer product companies in exchange for up-front fees, milestone payments, and/or royalty payments. Licensing covers the delivery of fat-soluble active molecules and drugs.
  2. Toll Processing: Lexaria offers dietary supplement GMP-grade intermediate formulations to corporate clients on a toll processing basis, providing manufacturing/processing services for DehydraTECH-enhanced products.
  3. Research and Development Services: Lexaria conducts contract research and formulation development services for pharmaceutical partners, including CRO contracts for GLP-1 studies and material transfer agreements (MTAs) with pharmaceutical companies evaluating DehydraTECH.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Lexaria Bioscience product offering

Product offering

Core offering

Lexaria Bioscience develops and out-licenses its proprietary DehydraTECH drug delivery platform technology, which enhances oral absorption of fat-soluble active pharmaceutical ingredients (APIs) and bioactive compounds. The technology uses fatty acid-rich triglyceride oils and controlled dehydration synthesis to associate payloads at a molecular level, enabling improved bioavailability, taste/odor masking, blood-brain barrier crossing, and reduced gastrointestinal side effects. Lexaria monetizes DehydraTECH through licensing deals, contract research, and toll processing services to pharmaceutical, biotech, and consumer product companies worldwide.

Product overview

Lexaria Bioscience Corp. is a biotechnology company offering its proprietary DehydraTECH drug delivery platform technology, which improves oral absorption of APIs. The core offering is DehydraTECH, available in versions including DehydraTECH 2.0 for enhanced performance. The company operates five subsidiaries: Lexaria Pharmaceutical Corp. (pharmaceuticals for hypertension, antivirals, epilepsy), Lexaria Nicotine LLC (oral nicotine products), Lexaria Hemp Corp. (hemp B2B), Lexaria Canpharm ULC (Health Canada licensed lab), and Lexaria Nutraceutical Corp. (consumer goods). Key product applications include DehydraTECH-CBD for hypertension, DehydraTECH-GLP-1 for diabetes/weight loss, and DehydraTECH-Nicotine for oral delivery. The company licenses its technology to pharmaceutical and consumer product companies worldwide.

Differentiator

Problem solved

Functional benefit

Brands

  • DehydraTECH: Proprietary drug delivery-enabling technology that improves the absorption of active pharmaceutical ingredients into the bloodstream, allowing greater drug effectiveness often with reduced side effects.
  • DehydraTECH 2.0
  • DehydraTECH-CBD
  • TurboCBD

Products and services

  • DehydraTECH Patented drug delivery platform technology that improves oral absorption of APIs into the bloodstream by mixing payloads with fatty acid-rich triglyceride oils and using controlled dehydration synthesis. Applicable to small and large molecule therapeutics in tablets, capsules, oral suspensions, and consumable liquids. Licensed to pharmaceutical, nutraceutical, and consumer product companies.
  • DehydraTECH 2.0 Enhanced second-generation formulation of DehydraTECH demonstrating up to 2,708% more CBD delivery into bloodstream compared to MCT control formulations in animal studies.
  • DehydraTECH-CBD CBD formulations processed with DehydraTECH for potential treatment of hypertension, heart disease, and seizure disorders. Demonstrated up to 23% blood pressure reduction in human clinical studies.
  • DehydraTECH-GLP-1 GLP-1 drug formulations (semaglutide, tirzepatide, liraglutide) enhanced with DehydraTECH to enable oral delivery and reduce gastrointestinal side effects compared to injectable formulations. DehydraTECH-semaglutide reduced overall side effects by 48% compared to Rybelsus.
  • DehydraTECH-Nicotine Oral nicotine formulations using DehydraTECH technology for faster blood absorption (10x to 20x faster than controls) and improved delivery compared to conventional oral nicotine products, including oral pouches and sublingual delivery.
  • Toll Processing Services GMP-grade intermediate formulations provided to corporate clients on a toll processing basis for DehydraTECH-enhanced dietary supplements and consumer products.
  • Contract Research and Formulation Development Services Research partnerships and CRO contracts for pharmaceutical partners evaluating DehydraTECH, including Material Transfer Agreements (MTAs) and pre-clinical/clinical study services for GLP-1, antiviral, and other applications.

Quantifiable outcome

  • DehydraTECH-semaglutide reduced overall side effects by 48% compared to Rybelsus; gastrointestinal side effects reduced by 55%
  • +7 more outcomes

Companies that use Lexaria Bioscience

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Lexaria Bioscience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Lexaria Bioscience partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • PharmaCO (Unnamed Pharmaceutical Company)coreStrategic or Co-development Partner · 4 September 2024Material Transfer Agreement (MTA) with an unnamed pharmaceutical company (referred to as 'PharmaCO') to evaluate DehydraTECH drug delivery technology for GLP-1 applications in a pre-clinical setting. The agreement was originally entered September 4, 2024 and extended through December 31, 2026. The extension maintains a temporary exclusive license and enables continued strategic planning discussions between the parties. Three GLP-1 studies are ongoing under this arrangement.
  • AltriacoreOEM/ Whitelabel/ Licensing PartnerLicensing agreement with Altria for the development of smokeless, oral-based nicotine products using DehydraTECH technology. Lexaria provides DehydraTECH powder-based nicotine formulations to be evaluated by Altria under agreements effective until March 31, 2023.
  • Nic's BeveragesminorOEM/ Whitelabel/ Licensing PartnerLicensed DehydraTECH technology to Nic's Beverages (owners of Nic's Cold Brew brand) for use in CBD beverages. Lexaria prepared proprietary DehydraTECH-powered CBD nanoemulsions for the company, demonstrating 93.4% potency retention after one year.
  • Amari Corp.minorOEM/ Whitelabel/ Licensing PartnerAmari Corp. uses DehydraTECH technology in their 'Everyday Calm' CBD product, which was named a Top CBD Product Pick by New Hope Network (host of Natural Products Expo).
  • Unnamed Multinational Pharmaceutical Companies (Multiple)minorStrategic or Co-development PartnerLexaria is in early-stage discussions with several multinational pharmaceutical companies regarding its oral GLP-1 drug delivery technology. These discussions are aimed at exploring potential licensing or partnership agreements for DehydraTECH in the GLP-1 space.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Lexaria Bioscience competitors and assessment

Company assessment

Direct peers

  • IntelGenx Technologies: Oral drug delivery platform company developing thin-film and other proprietary oral formulation technologies for pharmaceutical partners. Directly comparable as a small-cap oral drug delivery licensor pursuing pharma partnerships and reformulation opportunities.
  • Aprecia Pharmaceuticals: Pharmaceutical company built around a proprietary 3D-printing oral dosage form technology (ZipDose) for enhanced drug delivery. Comparable as a technology-licensing pharma focused on novel oral administration of established molecules.
  • Oramed Pharmaceuticals: Clinical-stage pharma developing an oral delivery platform (Protein Oral Delivery, POD) for peptides and proteins, including oral insulin and oral GLP-1. Directly comparable as a small-cap oral peptide delivery company pursuing pharma licensing.
  • Emisphere Technologies: Pioneer in oral drug delivery using the Eligen carrier technology to enable absorption of macromolecules. Closely comparable to Lexaria as an oral bioavailability platform licensor to large pharma partners.
  • BioDelivery Sciences International: Specialty pharma built on proprietary drug delivery technologies (e.g., BEMA, BioErodible MucoAdhesive) for pain and addiction therapies. Comparable as a delivery-platform-driven pharma pursuing both in-house and partner products.
  • Enteris BioPharma: Clinical-stage oral peptide delivery company offering Peptelligence and ProPerma formulation technologies and contract manufacturing. Comparable to Lexaria for its focus on oral peptide/GLP-1 reformulation and pharma partnership model.
  • CURE Pharmaceutical: Drug delivery company developing the CUREform platform for oral thin-film and multi-layer tablets with improved bioavailability. Comparable as a small-cap proprietary oral delivery technology licensor.

Broad incumbents

  • Catalent: Large global drug delivery and contract development/manufacturing organization offering a wide range of bioavailability-enhancing formulation services across multiple modalities. Comparable as an incumbent oral bioavailability and drug delivery partner, though at much greater scale and breadth than Lexaria.
  • Lonza Group: Global contract development and manufacturing organization serving pharma and biotech with drug substance, drug product, and specialized delivery capabilities including oral bioavailability. Comparable as a broad incumbent in pharma drug delivery services that Lexaria competes against for partner attention.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Lexaria Bioscience social profiles

Digital presence

Lexaria Bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lexaria Bioscience leadership team

Management profile

Number of profiles

Profiles11 records

Lexaria Bioscience subsidiaries and ownership

Company hierarchy

Subsidiaries6 records

Lexaria Bioscience funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lexaria Bioscience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lexaria Bioscience

What does Lexaria Bioscience do?

Lexaria Bioscience develops and out-licenses its proprietary DehydraTECH drug delivery platform technology, which enhances oral absorption of fat-soluble active pharmaceutical ingredients (APIs) and bioactive compounds. The technology uses fatty acid-rich triglyceride oils and controlled dehydration synthesis to associate payloads at a molecular level, enabling improved bioavailability, taste/odor masking, blood-brain barrier crossing, and reduced gastrointestinal side effects. Lexaria monetizes DehydraTECH through licensing deals, contract research, and toll processing services to pharmaceutical, biotech, and consumer product companies worldwide.

Is Lexaria Bioscience a public or private company?

Lexaria Bioscience is a public company. It is classified as public and is currently operating.

When was Lexaria Bioscience founded?

Lexaria Bioscience was founded in 2014. It employs 1 to 10 people.

Where is Lexaria Bioscience based?

Lexaria Bioscience is headquartered in Kelowna, Canada, in the North America region.

How does Lexaria Bioscience make money?

Three revenue lines are on record. Technology Licensing is the primary driver. The others are toll Processing and research and Development Services.

Who are Lexaria Bioscience's main competitors?

Direct peers on record are IntelGenx Technologies, Aprecia Pharmaceuticals, Oramed Pharmaceuticals, Emisphere Technologies, BioDelivery Sciences International, Enteris BioPharma and CURE Pharmaceutical. Broad incumbents are Catalent and Lonza Group.

Does Lexaria Bioscience have an API?

No public API is recorded for Lexaria Bioscience.

What industry is Lexaria Bioscience in?

Lexaria Bioscience's product category is Drug Delivery Technology. Its primary akta.pro industry code is AFAJACAF, Hydrocolloid Stabilizers (Xanthan, Guar, Locust Bean, Carrageenan, Alginate, Pectin, Cellulose), with a secondary code of AFAJACAK, Beverage Emulsions & Clouding Agents (Flavor Emulsions, Weighting Agents). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewLexaria Bioscience Corp. (LEXX) Fully Enrolls GLP-1-H26-7; Dosing On ScheduleLexaria Bioscience Corp. said its Human Pilot Study #7 (GLP-1-H26-7) reached full enrollment and is dosing on schedule, comparing two DehydraTECH-semaglutide compositions to Wegovy tablets over 5 weeks. Final dosing is expected to complete in mid-November, with analyses to follow.American Banking and Market NewsContrasting Siga Technologies (NASDAQ:SIGA) & Lexaria Bioscience (NASDAQ:LEXX)Siga Technologies and Lexaria Bioscience are compared on profitability, valuation, and analyst ratings. Siga has higher revenue ($94.57M vs $710K) and a lower P/E ratio, while Lexaria has a stronger consensus rating and a $22.50 price target implying 588% upside.Markets DailyLexaria Bioscience (NASDAQ:LEXX) vs. Siga Technologies (NASDAQ:SIGA) Head-To-Head ComparisonSiga Technologies and Lexaria Bioscience are compared on institutional ownership, profitability, and analyst ratings. Siga has higher revenue and earnings, while Lexaria has a stronger consensus rating and higher upside. Lexaria's beta is lower, indicating less volatility.American Banking and Market NewsFinancial Survey: Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) & Lexaria Bioscience (NASDAQ:LEXX)Shionogi & Co., Ltd. Unsponsored ADR and Lexaria Bioscience are compared on risk, profitability, earnings, analyst recommendations, institutional ownership, dividends, and valuation. Shionogi beats Lexaria on 9 of 15 factors, with higher revenue and earnings, while Lexaria has a lower price-to-earnings ratio and higher institutional ownership.Defense WorldLexaria Bioscience (NASDAQ:LEXX) and Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Critical ContrastShionogi & Co., Ltd. and Lexaria Bioscience are compared across analyst recommendations, dividends, risk, institutional ownership, profitability, valuation, and earnings. Shionogi beats Lexaria on 9 of 15 factors, with higher revenue and earnings, while Lexaria has a lower P/E ratio and a consensus price target of $22.50.American Banking and Market NewsHead-To-Head Comparison: Lexaria Bioscience (NASDAQ:LEXX) and Sonoma Pharmaceuticals (NASDAQ:SNOA)Lexaria Bioscience and Sonoma Pharmaceuticals are compared across earnings, institutional ownership, and valuation. Lexaria beats Sonoma on 8 of 14 factors, with a consensus price target of $22.50 implying 557.89% upside. Sonoma has higher revenue and a lower P/E ratio.Ticker ReportTalphera (NASDAQ:TLPH) vs. Lexaria Bioscience (NASDAQ:LEXX) Head-To-Head ComparisonTalphera and Lexaria Bioscience are compared on valuation, risk, and analyst ratings. Lexaria has higher revenue and earnings but a lower upside target, while Talphera trades at a lower P/E ratio. Talphera beats Lexaria on 8 of 13 factors.YahooLexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross ProceedsLexaria Bioscience closed the exercise of warrants to purchase 453,969 shares at a reduced price of $12.92 per share, generating approximately $5.9 million in gross proceeds. The company issued new Series A and Series B warrants to purchase the same number of shares, with proceeds intended for working capital and general corporate purposes.FinancialContent Business PageLexaria Announces Closing of Exercise of Warrants For Approximately $5.9 Million in Gross ProceedsLexaria Bioscience closed the exercise of warrants to purchase 453,969 shares at a reduced price of $12.92 per share, generating approximately $5.9 million in gross proceeds. The company issued new Series A and Series B warrants to purchase the same number of shares, with proceeds intended for working capital and general corporate purposes.Stock TitanLexaria Closes $5.9M Warrant Exercise OfferingLexaria Bioscience closed a warrant exercise offering on October 16, 2024, raising approximately $5.9 million in gross proceeds. The company issued new Series A and B warrants to purchase up to 453,969 shares at $12.67 per share. Proceeds will be used for working capital and general corporate purposes.